NAD-supplementation in Drug naïve Parkinson's Disease

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03816020
• Date of registration: 07/12/2018
• Prospective Registration: Yes
• Primary sponsor: Haukeland University Hospital
• Public title: NAD-supplementation in Drug naïve Parkinson's Disease NAD-PARK
• Scientific title: NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease
• Date of first enrolment: March 9, 2019
• Target sample size: 30
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03816020
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Care Provider, Investigator).
• Phase: N/A

Countries of recruitment

Norway

Contacts

• Name: Charalampos Tzoulis, PhD
• Affiliation: Nevro-Sysmed

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Newly diagnosed with PD

2. Drug naïve with respect to dopaminergic treatment

3. Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic
criteria for PD

Exclusion Criteria:

1. [¹²³I]FP-CIT single photon emission CT (DaTscan) does not show nigrostriatal
degeneration.

2. Magnetic resonance imaging (MRI) suggestive of atypical parkinsonsism.

3. Dementia or other neurological disorder at baseline visit

4. Metabolic, neoplastic, or other physically or mentally debilitating disorder at
baseline visit



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Parkinson Disease

Neurodegenerative Diseases

Intervention(s)

Other: Placebo

Dietary Supplement: Nicotinamide Riboside

Primary Outcome(s)

PDRP changes from NR use [Time Frame: 4 weeks]

Secondary Outcome(s)

Motoric change of symptoms from NR use [Time Frame: 4 weeks]

Secondary ID(s)

2018/597

Source(s) of Monetary Support

Please refer to primary and secondary sponsors